Profound Medical Corp (PROF)

Profound Medical Corp.'s stock price has been impacted by several events over the past six months. The company missed revenue expectations in its Q4 2025 earnings report, leading to a stock price decline. The CAPTAIN trial, comparing the TULSA Procedure to robotic radical prostatectomy, met its primary safety endpoint. TULSA-PRO milestones include Texas Prostate achieving its 100th TULSA Procedure, the installed base reaching 78 systems, and Johns Hopkins and Mount Sinai Hospitals treating their first patients using TULSA-PRO. In December 2025, the company announced expected funding and filed a follow-on equity offering.

The provided search results do not contain explicit information regarding demand seasonality for Profound Medical Corp.'s products and services. The company generates revenue from both capital equipment sales and recurring sales of single-use devices and related services, which might suggest a more consistent demand for the recurring revenue stream. However, no specific seasonal trends were identified.

Profound Medical Corp. is a commercial-stage medical device company specializing in AI-powered, MRI-guided, incision-free therapeutic systems for tissue ablation, operating in the Healthcare sector, specifically the Medical Devices and Instruments industry. Its flagship product, TULSA-PRO, integrates real-time MRI, AI, robotic ultrasound, and temperature feedback for incision- and radiation-free prostate tissue ablation, while preserving surrounding nerves and anatomy. TULSA-PRO is used for various prostate conditions and has received regulatory approvals in multiple countries. Profound Medical also commercializes Sonalleve, a therapeutic platform for non-invasive ablation, approved for treating uterine fibroids and other conditions. The company generates revenue through capital equipment sales and recurring sales of single-use devices and related services.

Profound Medical Corp. is incorporated in Ontario, Canada, with its corporate office in Mississauga. The company operates and markets its products in Canada, the United States, Germany, Finland, and China. It has distribution agreements for TULSA-PRO and Sonalleve in regions including Canada, Saudi Arabia, Australia, and New Zealand. Sonalleve is primarily marketed in European and Asian markets.

Profound Medical Corp.'s brand reputation has been positively influenced by clinical milestones and growing adoption of TULSA-PRO. The successful CAPTAIN trial and increasing TULSA-PRO installations indicate strong market acceptance. Adoptions by institutions like Johns Hopkins and Mount Sinai Hospitals further bolster the company's standing. The company was honored with INOVAIT's Mount Logan Award for the TULSA Procedure. The celebration of 500 Sonalleve procedures also highlights the expansion of incision-free care for women's health. While the Q4 2025 revenue miss negatively impacted the stock price, the company is focused on a path to profitable growth.

Profound Medical Corp. has 62 institutional owners and shareholders, holding 15,238,347 shares as of April 8, 2026. Major institutional shareholders include FIL Ltd, Gagnon Securities Llc and Rosalind Advisors, Inc.. Arun Swarup Menawat, the CEO, is the largest individual shareholder, owning 587,089 shares, representing 1.62% of the company.